World Stem Cell Summit 2010

Wednesday, November 11, 2009

Leukemia - Table of Contents alert Volume 23 Issue 11


November 2009 Volume 23 Number 11, pp 1939 - 2187


New in January 2010: Cell Death & Disease

Online. Open access. Author pays.

Brought to you by the editorial team of Cell Death & Differentiation,
Cell Death & Disease is a peer-reviewed author-pays online journal that
publishes full-length papers, reviews, and commentaries describing
original research in the field of translational cell death.

Sign up today for Cell Death & Disease's ToC-alert at
and be notified when the journal launches in January 2010.


Why Publish in Leukemia?

Efficient peer-review, hassle-free submission, recognition...

Papers benefit from wide readership through hosting on and
inclusion in the leading abstracting and indexing services.
Rapid publication is also assured through Advance Online Publication.
To read the full Guide to Authors for Leukemia, visit


Commentary on Perrone et al.: 'Vitamin C: not for breakfast
anymore... if you have myeloma'
R D Harvey, J Nettles, B Wang, S-Y Sun and S Lonial

The molecular characterization and clinical management of multiple
myeloma in the post-genome era
Y Zhou, B Barlogie and J D Shaughnessy

Harmonization of molecular monitoring of CML therapy in Europe
M C Muller, N C P Cross, P Erben, T Schenk, B Hanfstein, T Ernst,
R Hehlmann, S Branford, G Saglio and A Hochhaus

Proteasome inhibitors in the treatment of multiple myeloma
J J Shah and R Z Orlowski

Management guidelines for the use of alemtuzumab in chronic
lymphocytic leukemia
A Osterborg, R Foa, R F Bezares, C Dearden, M J S Dyer, C Geisler,
T S Lin, M Montillo, M H J van Oers, C-M Wendtner and K R Rai

PAX5 mutations occur frequently in adult B-cell progenitor acute
lymphoblastic leukemia and PAX5 haploinsufficiency is associated
with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study
J Familiades, M Bousquet, M Lafage-Pochitaloff, M-C Bene, K Beldjord,
J De Vos, N Dastugue, E Coyaud, S Struski, C Quelen,
N Prade-Houdellier, S Dobbelstein, J-M Cayuela, J Soulier, N Grardel,
C Preudhomme, H Cave, O Blanchet, V Lheritier, A Delannoy,
Y Chalandon, N Ifrah, A Pigneux, P Brousset, E A Macintyre, F Huguet,
H Dombret, C Broccardo and E Delabesse

Nilotinib concentration in cell lines and primary CD34+ chronic
myeloid leukemia cells is not mediated by active uptake or efflux
by major drug transporters
A Davies, N E Jordanides, A Giannoudis, C M Lucas, S Hatziieremia,
R J Harris, H G Jorgensen, T L Holyoake, M Pirmohamed, R E Clark
and J C Mountford

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in
CLL patients after rituximab-containing immunochemotherapy: a
comparative analysis
S Bottcher, S Stilgenbauer, R Busch, M Bruggemann, T Raff, C Pott,
K Fischer, G Fingerle-Rowson, H Dohner, M Hallek, M Kneba and
M Ritgen on behalf of the German CLL study group

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle
cell lymphoma and chronic lymphocytic leukemia
A Farfsing, F Engel, M Seiffert, E Hartmann, G Ott, A Rosenwald,
S Stilgenbauer, H Dohner, M Boutros, P Lichter and A Pscherer

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic
leukaemia (CLL): results of a prospective, single-arm multicentre study
A Cortelezzi, M C Pasquini, A Gardellini, U Gianelli, A Bossi,
G Reda, B Sarina, P Musto, W Barcellini, A Neri and G L Deliliers

The BH3 mimetic compound, ABT-737, synergizes with a range of
cytotoxic chemotherapy agents in chronic lymphocytic leukemia
K D Mason, S L Khaw, K C Rayeroux, E Chew, E F Lee, W D Fairlie,
A P Grigg, J F Seymour, J Szer, D C S Huang and A W Roberts

Novel epigenetic mechanisms that control pluripotency and quiescence
of adult bone marrow-derived Oct4+ very small embryonic-like
stem cells
D M Shin, E K Zuba-Surma, W Wu, J Ratajczak, M Wysoczynski,
M Z Ratajczak and M Kucia

Impaired mobilization of hematopoietic stem/progenitor cells in
C5-deficient mice supports the pivotal involvement of innate immunity
in this process and reveals novel promobilization effects of
H M Lee, W Wu, M Wysoczynski, R Liu, E K Zuba-Surma, M Kucia,
J Ratajczak and M Z Ratajczak

The TLR1/2 agonist PAM3CSK4 instructs commitment of human
hematopoietic stem cells to a myeloid cell fate
K De Luca, V Frances-Duvert, M-J Asensio, R Ihsani, E Debien,
M Taillardet, E Verhoeyen, C Bella, S Lantheaume, L Genestier
and T Defrance

Defining origins of malignant B cells: a new circulating normal human
IgM+D+ B-cell subset lacking CD27 expression and displaying
somatically mutated IGHV genes as a relevant memory population
N Weston-Bell, M Townsend, G Di Genova, F Forconi and S S Sahota

Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1
J-M Terme, V Mocquet, A-S Kuhlmann, L Zane, F Mortreux, E Wattel,
M Duc Dodon and P Jalinot

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces
apoptosis and cellular senescence in adult T-cell leukemia cells
H Hasegawa, Y Yamada, H Iha, K Tsukasaki, K Nagai, S Atogami,
K Sugahara, K Tsuruda, A Ishizaki and S Kamihira

IL-6, but not IFN-[gamma], triggers apoptosis and inhibits in vivo
growth of human malignant T cells on STAT3 silencing
G Regis, L Icardi, L Conti, R Chiarle, R Piva, M Giovarelli,
V Poli and F Novelli

A robust xenotransplantation model for acute myeloid leukemia
P V Sanchez, R L Perry, J E Sarry, A E Perl, K Murphy, C R Swider,
A Bagg, J K Choi, J A Biegel, G Danet-Desnoyers and M Carroll

Different proliferative and survival capacity of CLL-cells in a newly
established in vitro model for pseudofollicles
M Plander, S Seegers, P Ugocsai, S Diermeier-Daucher, J Ivanyi,
G Schmitz, F Hofstadter, S Schwarz, E Orso, R Knuchel and G Brockhoff

Gene expression profiling of isolated tumour cells from anaplastic
large cell lymphomas: insights into its cellular origin, pathogenesis
and relation to Hodgkin lymphoma
S Eckerle, V Brune, C Doring, E Tiacci, V Bohle, C Sundstrom,
R Kodet, M Paulli, B Falini, W Klapper, A B Chaubert, K Willenbrock,
D Metzler, A Brauninger, R Kuppers and M-L Hansmann

Soluble decoy receptor 3 modulates the survival and formation of
osteoclasts from multiple myeloma bone disease patients
S Colucci, G Brunetti, G Mori, A Oranger, M Centonze, C Mori,
F P Cantatore, R Tamma, R Rizzi, V Liso, A Zallone and M Grano

Long-term follow-up on overall survival from the MM-009 and MM-010
phase III trials of lenalidomide plus dexamethasone in patients with
relapsed or refractory multiple myeloma
M A Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal,
E A Stadtmauer, M T Petrucci, Z Yu, M Olesnyckyj, J B Zeldis,
R D Knight and D M Weber

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with
interstitial del(14)(q24.1q32.33)
I Nagel, S Bug, H Tonnies, O Ammerpohl, J Richter, I Vater,
E Callet-Bauchu, M J Calasanz, J A Martinez-Climent, C Bastard,
M Salido, E Schroers, J I Martin-Subero, S Gesk, L Harder,
A Majid, M J S Dyer and R Siebert

Imatinib mesylate causes growth plate closure in vivo
K Vandyke, A L Dewar, S Fitter, D Menicanin, L B To, T P Hughes and
C W Zannettino

Mutational analysis of candidate tumor-associated genes in acute
megakaryoblastic leukemia
R Bhat, S Malinge, A S Gamis, A D Sorrell, J M Hilden,
R P Ketterling, E Paietta, M S Tallman and J D Crispino

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia
have distinctive gene expression signatures
I Del Giudice, N Osuji, T Dexter, V Brito-Babapulle, N Parry-Jones,
S Chiaretti, M Messina, G Morgan, D Catovsky and E Matutes

Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia
cells to glucocorticoid-induced apoptosis
K Eberhart, K Renner, I Ritter, M Kastenberger, K Singer,
C Hellerbrand, M Kreutz, R Kofler and P J Oefner

Sunitinib, an orally available receptor tyrosine kinase inhibitor,
induces monocytic differentiation of acute myelogenous leukemia
cells that is enhanced by 1,25-dihydroxyvitamin D3
C Nishioka, T Ikezoe, J Yang and A Yokoyama

miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic
lymphocytic leukaemia?
B Cardinaud, C Moreilhon, B Marcet, K Robbe-Sermesant, K LeBrigand,
B Mari, V Eclache, F Cymbalista, S Raynaud and P Barbry

Increased expression of macrophage inflammatory protein-1[alpha] on
trephine biopsies correlates with extensive bone disease, increased
angiogenesis and advanced stage in newly diagnosed patients with
multiple myeloma
M Roussou, A Tasidou, M A Dimopoulos, E Kastritis, M Migkou,
D Christoulas, M Gavriatopoulou, F Zagouri, C Matsouka,
D Anagnostou and E Terpos

Acquisition of a multidrug-resistant phenotype with a proteasome
inhibitor in multiple myeloma
D Gutman, A A Morales and L H Boise

Mutations of ASXL1 gene in myeloproliferative neoplasms
N Carbuccia, A Murati, V Trouplin, M Brecqueville, J Adelaide, J Rey,
W Vainchenker, O A Bernard, M Chaffanet, N Vey, D Birnbaum and
M J Mozziconacci

HTLV-I infection of WE17/10 CD4+ cell line leads to progressive
alteration of Ca2+ influx that eventually results in loss of CD7
expression and activation of an antiapoptotic pathway involving
AKT and BAD which paves the way for malignant transformation
H Akl, B M Badran, N El Zein, F Bex, C Sotiriou, K E Willard-Gallo,
A Burny and P Martiat


Launching in 2010: Cell Death & Disease

Online submission is now open at

- Cell Death & Disease focuses on the translational implications of cell death
- Brought to you from the same editorial team as Cell Death & Differentiation
- Top-quality Editors: Guido Kroemer, Gerry Melino, Pierluigi Nicotera
- Efficient peer-review and fast publication

Contributions of broad biological interest and impact are especially
encouraged. Submit today at



You have been sent this Table of Contents Alert because you have
opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by
modifying your preferences on your account at:
(You will need to log in to be recognised as a

For further technical assistance, please contact our registration

For print subscription enquiries, please contact our subscription

For other enquiries, please contact customer feedback

Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego
- San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England
and Wales under company number 785998 and whose registered office
is located at Brunel Road, Houndmills, Basingstoke,
Hampshire RG21 6XS.

© Copyright 2009 Nature Publishing Group



Any Comments ?.......


World Time